Pharmacology of nomifensine: a review of animal studies.
Nomifensine has demonstrated efficacy in several animal models that have been found to be predictive of clinical antidepressant activity, and has also been found to have a low potential for both cardiovascular and anticholinergic side effects. A comparison of nomifensine's profile with those of standard antidepressant agents shows this drug to possess clear advantages which may make it an attractive choice for the treatment of endogenous depression.
D000109:Acetylcholine / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000378:metabolism; D000374:Aggression / Q000187:drug effects; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects / Q000201:enzymology; D003866:Depressive Disorder / Q000188:drug therapy; D004298:Dopamine / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D004562:Electrocardiography; D006168:Guinea Pigs; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007099:Imipramine / Q000009:adverse effects / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology*; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D009627:Nomifensine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D012110:Reserpine / Q000009:adverse effects / Q000494:pharmacology
D007546:Isoquinolines; D009627:Nomifensine; D012110:Reserpine; D000262:Adenylyl Cyclases; D000109:Acetylcholine; D007099:Imipramine; D004298:Dopamine